← Leaderboards
Donna Arvans
Oxalo Therapeutics, Inc.
$2,299,991
Attributed
$2,299,991
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1000K · FY2018–20$1M$750K$500K$250K$0
'18
'19
'20
Funding mix
By agency
NIH$2,299,991 · 1
By mechanism
R42$2,299,991 · 1
Top collaborators
No co-investigators on record.
Most similar at Oxalo Therapeutics, Inc.
Same institution · by research overlap
- Hatim A Hassan$612,497
- Altayeb Alshaikh$112,498
- Jessica A Rodriguez Arias$500,000
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectBaseAmino AcidsBiological ProductsBloodCaco-2 CellsCalcium OxalateCapsuleCellsChicagoChronic Kidney FailureCommercializationConditioned Culture MediaCrystallizationDesignDietDrug DevelopmentDrug KineticsDrug TargetingEmergency Department VisitEnd Stage Renal FailureEnteralExcretory FunctionFamily